Literature DB >> 11287445

Effects of retinoids on cancerous phenotype and apoptosis in organotypic cultures of ovarian carcinoma.

S Guruswamy1, S Lightfoot, M A Gold, R Hassan, K D Berlin, R T Ivey, D M Benbrook.   

Abstract

BACKGROUND: Retinoic acid analogues, called retinoids, have shown promise in clinical trials in preventing breast and ovarian cancers. Classic retinoids bind to retinoic acid receptors, which regulate cell growth. Some novel retinoids, such as fenretinide, i.e., N-(4-hydroxyphenyl)retinamide (4-HPR), induce apoptosis through retinoic acid receptor-independent mechanisms; however, they appear to do so only at concentrations above those achieved in clinical chemoprevention trials. At lower concentrations (< or =1 microM), 4-HPR acts like classic retinoids, by inducing differentiation through a receptor-dependent mechanism. Our goal was to compare the effects of novel receptor-independent (apoptotic) retinoids with those of classic growth-inhibitory retinoids at clinically achievable doses on growth, differentiation, and apoptosis in ovarian tissue.
METHODS: Four receptor-independent (apoptotic) and seven growth-inhibitory retinoids, including synthetic, low-toxicity compounds called heteroarotinoids, were administered at concentrations of 1 microM to organotypic cultures of ovarian primary and cancer cell lines: OVCAR-3, Caov-3, and SK-OV-3. After fixation, embedding, and sectioning, the growth fraction was quantified by measuring expression of the proliferation marker Ki-67/myb, differentiation was assessed by expression of mucin, and apoptosis was evaluated by the TUNEL assay. Spearman correlation analysis was performed on the data, and all P values were two-sided.
RESULTS: All 11 retinoids reversed characteristics associated with the cancerous phenotype in all neoplastic cultures. Glandular structures were observed consistently in retinoid-treated, but not in untreated, OVCAR-3 and Caov-3 cultures. All retinoids decreased growth fractions, and some increased mucin expression. All receptor-independent retinoids and two receptor-dependent retinoids induced apoptosis, and the induction correlated significantly with increased expression of the mucin MUC1 (r =.83; P =.03). Retinoids with ester-linking groups did not induce apoptosis but decreased the growth fraction in correlation with MUC1 induction (r = -.93; P =.02).
CONCLUSIONS: At clinically achievable concentrations, all retinoids tested decrease the growth fraction, induce differentiation and apoptosis. Induction of MUC1 expression is implicated in the mechanisms of action.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11287445     DOI: 10.1093/jnci/93.7.516

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  19 in total

1.  Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53.

Authors:  Satish K Ramraj; Sugantha P Elayapillai; Richard C Pelikan; Yan D Zhao; Zitha R Isingizwe; Amy L Kennedy; Stanley A Lightfoot; Doris M Benbrook
Journal:  Int J Cancer       Date:  2020-01-08       Impact factor: 7.396

2.  Flexible heteroarotinoids (Flex-Hets) exhibit improved therapeutic ratios as anti-cancer agents over retinoic acid receptor agonists.

Authors:  Doris M Benbrook; Scott A Kamelle; Suresh B Guruswamy; Stan A Lightfoot; Teresa L Rutledge; Natalie S Gould; Bethany N Hannafon; S Terence Dunn; K Darrell Berlin
Journal:  Invest New Drugs       Date:  2005-10       Impact factor: 3.850

3.  Chemoprevention of colon and small intestinal tumorigenesis in APC(min/+) mice by SHetA2 (NSC721689) without toxicity.

Authors:  Doris Mangiaracina Benbrook; Suresh Guruswamy; Yuhong Wang; Zhongjie Sun; Altaf Mohammed; Yuting Zhang; Qian Li; Chinthalapally V Rao
Journal:  Cancer Prev Res (Phila)       Date:  2013-07-12

4.  Flex-Hets differentially induce apoptosis in cancer over normal cells by directly targeting mitochondria.

Authors:  Tongzu Liu; Bethany Hannafon; Lance Gill; William Kelly; Doris Benbrook
Journal:  Mol Cancer Ther       Date:  2007-06       Impact factor: 6.261

5.  Flexible heteroarotinoid (Flex-Het) SHetA2 inhibits angiogenesis in vitro and in vivo.

Authors:  Tashanna Myers; Shylet Chengedza; Stan Lightfoot; Yanfang Pan; Daynelle Dedmond; Lauren Cole; Yuhong Tang; Doris M Benbrook
Journal:  Invest New Drugs       Date:  2008-09-18       Impact factor: 3.850

6.  Heteroarotinoids with anti-cancer activity against ovarian cancer cells.

Authors:  Thanh C Le; K Darrell Berlin; Stacy D Benson; Margaret A Eastman; Gianna Bell-Eunice; Anna C Nelson; Doris M Benbrook
Journal:  Open Med Chem J       Date:  2007-10-24

7.  Retinoid activation of retinoic acid receptor but not retinoid X receptor is sufficient to rescue lethal defect in retinoic acid synthesis.

Authors:  Felix A Mic; Andrei Molotkov; Doris M Benbrook; Gregg Duester
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-02       Impact factor: 11.205

8.  Sensitivities of Uterine Adenocarcinoma, Mixed Mullerian Tumor (MMT) and Sarcoma Cell Lines to Chemotherapeutic Agents and a Flex-Het Drug.

Authors:  Johnny Hyde; Doris M Benbrook
Journal:  Am J Pharmacol Toxicol       Date:  2006-01-01

9.  Effect of all-trans retinoic acid on tissue dynamics of choriocarcinoma cell lines: an organotypic model.

Authors:  P M Chiu; H C Feng; D M Benbrook; H Y S Ngan; U S Khoo; W C Xue; S W Tsao; K W Chan; A N Y Cheung
Journal:  J Clin Pathol       Date:  2006-02-06       Impact factor: 3.411

10.  Gene expression analysis of biological systems driving an organotypic model of endometrial carcinogenesis and chemoprevention.

Authors:  Doris M Benbrook; Stan Lightfoot; James Ranger-Moore; Tongzu Liu; Shylet Chengedza; William L Berry; Igor Dozmorov
Journal:  Gene Regul Syst Bio       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.